DWP16001 + DWC202101

DWP16001 + DWC202101 is a combination drug, but there is only clear information about DWP16001, which is also known as enavogliflozin. DWP16001/enavogliflozin is a novel, selective sodium-glucose cotransporter 2 (SGLT2) inhibitor developed for the treatment of type 2 diabetes mellitus. It inhibits SGLT2 in the kidneys, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose levels. DWP16001 has shown significant efficacy in reducing HbA1c, body weight, and systolic blood pressure without serious increases in adverse events, and is under investigation for cardiovascular and renal outcome benefits in type 2 diabetes. No detailed mechanism, class, or development status information could be found for DWC202101, and it does not appear in major clinical or pharmacological databases as of this search. There are no known studies of this exact combination or of DWC202101 individually, so the pharmacological profile and intent of this combination remain unresolved. DWP16001 was developed by Daewoong Pharmaceutical and GC Pharma (Green Cross Corp).